<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01528046</url>
  </required_header>
  <id_info>
    <org_study_id>MCC-16962</org_study_id>
    <secondary_id>SP003</secondary_id>
    <nct_id>NCT01528046</nct_id>
  </id_info>
  <brief_title>Metformin in Children With Relapsed or Refractory Solid Tumors</brief_title>
  <official_title>A Phase I Trial of Dose Escalation of Metformin in Combination With Vincristine, Irinotecan, and Temozolomide in Children With Relapsed or Refractory Solid Tumors</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>H. Lee Moffitt Cancer Center and Research Institute</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Pediatric Cancer Foundation</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>H. Lee Moffitt Cancer Center and Research Institute</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      H. Lee Moffitt Cancer Center and Research Institute will be the Sunshine Project Coordinator,
      but will not be recruiting locally.

      The purpose of this study is to evaluate the tolerability and safety of escalating doses of
      metformin on a backbone of vincristine, irinotecan and temozolomide (VIT) in children with
      recurrent and refractory solid tumors.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Metformin is an oral anti-diabetes medication that activates AMP-activated protein kinase
      (AMPK). Recent data from in vitro and in vivo experiments, as well as epidemiologic
      retrospective analyses, suggest that metformin has anti-cancer activity. Vincristine,
      irinotecan, and temozolomide (VIT) is a combination of chemotherapeutic agents that have
      different mechanisms of action as well as disparate side effect profiles. Two recent phase 1
      trials have demonstrated that this regimen is safe and well-tolerated in children with
      relapsed and refractory solid tumors.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">April 25, 2012</start_date>
  <completion_date type="Anticipated">December 2019</completion_date>
  <primary_completion_date type="Anticipated">December 2018</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Maximum Tolerated Dose (MTD)</measure>
    <time_frame>Average of 3 Months</time_frame>
    <description>To determine the maximum tolerated dose (MTD) of metformin when given in conjunction with VIT in children with refractory and relapsed solid tumors.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of Participants with Antitumor Activity</measure>
    <time_frame>Average of 3 Months</time_frame>
    <description>To evaluate the antitumor activity of the addition of metformin to VIT.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics</measure>
    <time_frame>Average of 3 Months</time_frame>
    <description>To describe the pharmacokinetics of metformin in children with relapsed malignancies receiving VIT combination chemotherapy.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacodynamics</measure>
    <time_frame>Average of 3 Months</time_frame>
    <description>To define the pharmacodynamics of metformin.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Metformin Concentrations</measure>
    <time_frame>Average of 3 Months</time_frame>
    <description>To determine tissue and tumor metformin concentrations in patients undergoing resection.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">25</enrollment>
  <condition>Solid Tumors</condition>
  <condition>Primary Brain Tumors</condition>
  <arm_group>
    <arm_group_label>Metformin in Combination with VIT</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive metformin in combination with vincristine, irinotecan and temozolomide (VIT).</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Vincristine</intervention_name>
    <description>Vincristine (VCR) = 1.5 mg/m^2/day (maximum dose 2 mg), days 1 and 8, administered as intravenous (IV) bolus over 1-5 minutes</description>
    <arm_group_label>Metformin in Combination with VIT</arm_group_label>
    <other_name>VCR</other_name>
    <other_name>Oncovin</other_name>
    <other_name>NSC #067574</other_name>
    <other_name>Vincristine sulfate</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Irinotecan</intervention_name>
    <description>Irinotecan (IRN) = 50 mg/m^2/day, days 1-5, IV over 60 minutes</description>
    <arm_group_label>Metformin in Combination with VIT</arm_group_label>
    <other_name>CPT-11</other_name>
    <other_name>Camptothecin-11</other_name>
    <other_name>Camptosar ®</other_name>
    <other_name>NSC#616348</other_name>
    <other_name>IRN</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Temozolomide</intervention_name>
    <description>Temozolomide (TEM) = 50 mg/m^2/day by mouth (PO) Days 1-5</description>
    <arm_group_label>Metformin in Combination with VIT</arm_group_label>
    <other_name>Temodar™</other_name>
    <other_name>NSC #362856</other_name>
    <other_name>TEM</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Metformin</intervention_name>
    <description>Metformin (MET) = dose as per dose escalation, divided twice a day (BID), PO continuously for the 21 day cycle.</description>
    <arm_group_label>Metformin in Combination with VIT</arm_group_label>
    <other_name>Glucophage ®</other_name>
    <other_name>MET</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age: Patients must be &gt; 1 year of age and ≤ 18 years of age at time of initiation of
             protocol therapy.

          -  Diagnosis: Patients have a histologically or radiographically confirmed relapsed or
             refractory solid tumor or primary central nervous system (CNS) malignancy.

          -  Disease Status: Patients must have radiographically measurable disease.

          -  Therapeutic Options: Patients must have relapsed or refractory cancers for which there
             is no known curative option or other available therapy proven to prolong survival with
             an acceptable quality of life.

          -  Performance Level: Karnofsky ≥ 50% for patients older than 16 years old, and Lansky ≥
             50 for patients 1-16 years old.

          -  Prior Therapy: Patients may have received prior therapy including vincristine,
             irinotecan, or temozolomide. Patients may not have previously been treated with
             combination therapy of irinotecan and temozolomide.

          -  Patients must be fully recovered from the acute toxic effects of all prior
             chemotherapy, immunotherapy, or radiotherapy prior to entering this study.

               -  Myelosuppressive chemotherapy: Patients must not have received myelosuppressive
                  chemotherapy within 3 weeks of starting protocol therapy, or a minimum of six
                  weeks must have elapsed since prior nitrosurea chemotherapy.

               -  Hematopoietic growth factor: At least 7 days must have elapsed since the last
                  administration of filgrastim, or 14 days since administration of pegfilgrastim.

               -  Biologic (anti-neoplastic agent): At least 7 must have elapsed since the last
                  administration of any biologic agent.

               -  Radiation therapy (XRT): At least 14 days since the last dose of local palliative
                  radiation therapy. Greater than 6 months must have elapsed since the last day of
                  treatment if given total body irradiation, craniospinal irradiation.

               -  Autologous or Allogenic Stem Cell Transplant: Complete resolution of graft versus
                  host disease and no current need for immunosuppressive medication. Greater than 3
                  months must have elapsed since engraftment and no longer requiring transfusion of
                  platelets or injection of colony stimulating factors.

          -  Organ Function Requirements

               -  Bone Marrow Function: Peripheral absolute neutrophil count (ANC) ≥ 1000/μL;
                  Platelet count ≥ 100,000/μL (no platelet transfusion within 7 days prior to
                  obtaining laboratory result); Hemoglobin ≥ 8.0 gm/dL

               -  Adequate Renal Function: Creatinine clearance or glomerular filtration rate ≥
                  70ml/min/1.73m^2

               -  Adequate Liver Function: Total bilirubin ≤ 1.5x upper limit of normal (ULN) for
                  age; alanine transaminase (ALT) ≤ 5x ULN; Serum albumin ≥ 2gm/dL

          -  Informed Consent: All patients ≥ 18 years of age must sign a written informed consent.
             For patients &lt; 18 years old, the patient's parents or legal guardians must sign a
             written informed consent, unless the patient is an emancipated minor. Childhood
             Assent, when age appropriate as per institutional guidelines, should be signed by the
             participating patient.

        Exclusion Criteria:

          -  Significant organ dysfunction, not meeting inclusion criteria.

          -  Pregnancy or Breast-Feeding woman will not be entered on this study due to risks of
             fetal and teratogenic adverse events as seen in animal/human studies.

          -  Concomitant Medications:

               -  Growth factor: Growth factors that support platelet or white cell number of
                  function must not have been administered within the past 7 days.

               -  Steroids: Patients with CNS tumors who have not been on a stable or decreasing
                  dose of dexamethasone for the past 7 days.

               -  Investigational Drugs: Patients who are currently receiving another
                  investigational drug.

               -  Anti-cancer Agents: Patients who are currently receiving other anti-cancer
                  agents.

               -  Medication Allergy: Allergy or intolerance to agents on this protocol:
                  vincristine, irinotecan, temozolomide, or metformin; Allergy to cephalosporins.

               -  Infection: Patients who have uncontrolled infection, positive blood cultures
                  within the past 48 hours, or receiving treatment for Clostridium difficile
                  infection.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>1 Year</minimum_age>
    <maximum_age>18 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jonathan Gill, M.D.</last_name>
    <role>Study Chair</role>
    <affiliation>The Children's Hospital at Montefiore, Pediatric Cancer Foundation, Sunshine Project</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Damon Reed, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>H. Lee Moffitt Cancer Center and Research Institute</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Tiffany Smith</last_name>
    <phone>813-745-6250</phone>
    <email>tiffany.smith@moffitt.org</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Damon Reed, M.D.</last_name>
    <phone>813-745-2297</phone>
    <email>damon.reed@moffitt.org</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Connecticut Children's Medical Center</name>
      <address>
        <city>Hartford</city>
        <state>Connecticut</state>
        <zip>06106</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Robin Arens</last_name>
      <phone>860-545-9637</phone>
      <email>Rarens@ccmckids.org</email>
    </contact>
    <investigator>
      <last_name>Michael Isakoff, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Donna Boruchov, M.D.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Kerry Moss, M.D.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Andrea Orsey, M.D.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Nehal Parikh, M.D.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Arnold Altman, M.D.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Nemours/Alfred I. duPont Hospital for Children, Delaware</name>
      <address>
        <city>Wilmington</city>
        <state>Delaware</state>
        <zip>19803</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Debra J. Bertz</last_name>
      <phone>302-651-5757</phone>
      <email>debra.bertz@nemours.org</email>
    </contact>
    <investigator>
      <last_name>Edward A. Kolb, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Andrew Walter, M.D.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Jonathan Powell, M.D.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Emi Caywood, M.D.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Robin Miller, M.D.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Gregory Griffin, M.D.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Florida</name>
      <address>
        <city>Gainesville</city>
        <state>Florida</state>
        <zip>32611</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Terminated</status>
  </location>
  <location>
    <facility>
      <name>Nemours Children's Clinic</name>
      <address>
        <city>Jacksonville</city>
        <state>Florida</state>
        <zip>32207</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ingrid Ingram</last_name>
      <phone>904-697-3985</phone>
      <email>iingram@nemours.org</email>
    </contact>
    <investigator>
      <last_name>Scott Bradfield, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Eric Sandler, M.D.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Michael Joyce, M.D.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Cynthia Gauger, M.D.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Manisha Bansal, M.D.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Paul Pitel, M.D.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Holtz Children's Hospital at the University of Miami</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33124</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Myriam Zayas</last_name>
      <phone>305-243-7846</phone>
      <email>MZayas2@med.miami.edu</email>
    </contact>
    <investigator>
      <last_name>John Goldberg, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Cristina Fernandes, M.D.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Joanna Davis, M.D.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Antonello Podda, M.D.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Martin Andreansky, M.D.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Julio Barredo, M.D.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Ofelia Alvarez, M.D.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Johns Hopkins All Children's Hospital</name>
      <address>
        <city>Saint Petersburg</city>
        <state>Florida</state>
        <zip>33701</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ashley Repp, RN</last_name>
      <phone>727-767-4784</phone>
      <email>Ashley.Repp@allkids.org</email>
    </contact>
    <contact_backup>
      <last_name>Frances Hamblin</last_name>
      <phone>727-767-2423</phone>
      <email>frances.hamblin@allkids.org</email>
    </contact_backup>
    <investigator>
      <last_name>Damon Reed, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Irmel Ayala, M.D.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Gregory Hale, M.D.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Nanette Grana, M.D.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Stacie Stapleton, M.D.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Kelly Sawczyn, M.D.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Jennifer Mayer, M.D.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Jody Kerr, M.D.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Tampa General Hospital</name>
      <address>
        <city>Tampa</city>
        <state>Florida</state>
        <zip>33606</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Denise Fife</last_name>
      <phone>813-844-7829</phone>
      <email>dafife@tgh.org</email>
    </contact>
    <investigator>
      <last_name>Cameron Tebbi, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Kentucky</name>
      <address>
        <city>Lexington</city>
        <state>Kentucky</state>
        <zip>40536</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Tammy Taylor</last_name>
      <phone>859-323-6975</phone>
      <email>tammy.taylor@uky.edu</email>
    </contact>
    <investigator>
      <last_name>Lars Wagner, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Johns Hopkins Sidney Kimmel Comprehensive Cancer Center</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21231</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>David Loeb, M.D.</last_name>
      <phone>410-502-7247</phone>
      <email>loebda@jhmi.edu</email>
    </contact>
    <investigator>
      <last_name>David Loeb, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>The Children's Hospital at Montefiore</name>
      <address>
        <city>Bronx</city>
        <state>New York</state>
        <zip>10467</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Noam Zeffren</last_name>
      <phone>718-741-2356</phone>
      <email>nzeffren@montefiore.org</email>
    </contact>
    <investigator>
      <last_name>Jonathan Gill, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of North Carolina at Chapel Hill</name>
      <address>
        <city>Chapel Hill</city>
        <state>North Carolina</state>
        <zip>27599</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sharon Guerry</last_name>
      <phone>919-966-1178</phone>
    </contact>
    <contact_backup>
      <last_name>Patrick Thompson, M.D</last_name>
      <phone>919-966-1178</phone>
      <email>patom@email.unc.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Patrick Thompson, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Nationwide Children's Hospital</name>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <zip>43205</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Amy Yekisa</last_name>
      <phone>614-722-6570</phone>
      <email>Amy.Yekisa@nationwidechildrens.org</email>
    </contact>
    <investigator>
      <last_name>Bhuvana Setty, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Primary Children's Medical Center/Utah</name>
      <address>
        <city>Salt Lake City</city>
        <state>Utah</state>
        <zip>84113</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Melissa Bolton</last_name>
      <phone>801-213-3909</phone>
      <email>melissa.bolton@hsc.utah.edu</email>
    </contact>
    <investigator>
      <last_name>Holly Spraker-Perlman, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Richard Lemons, M.D., Ph.D.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Jennifer Wright, M.D.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.moffitt.org/research--clinical-trials/clinical-trials</url>
    <description>Moffitt Cancer Center Clinical Trials website</description>
  </link>
  <verification_date>January 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 3, 2012</study_first_submitted>
  <study_first_submitted_qc>February 6, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 7, 2012</study_first_posted>
  <last_update_submitted>January 9, 2018</last_update_submitted>
  <last_update_submitted_qc>January 9, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">January 11, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>central nervous system (CNS)</keyword>
  <keyword>malignancy</keyword>
  <keyword>relapsed</keyword>
  <keyword>refractory</keyword>
  <keyword>pediatric</keyword>
  <keyword>recurrent</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neoplasms</mesh_term>
    <mesh_term>Brain Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Metformin</mesh_term>
    <mesh_term>Irinotecan</mesh_term>
    <mesh_term>Camptothecin</mesh_term>
    <mesh_term>Vincristine</mesh_term>
    <mesh_term>Temozolomide</mesh_term>
    <mesh_term>Dacarbazine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

